Moderna COVID-19 Vaccine Data Bring Multivalent Vs. Monovalent Debate Into Focus
Phase II/III data for mRNA-1273.211 showed superiority against variants of concern to the original Spikevax, but Moderna’s top competitor has questioned the need for multivalent approaches.
You may also be interested in...
The bivalent vaccine is likely to get regulatory support, along with government contracts, but competitors, notably Moderna, will also step into the ring.
The path for developing a variant-adapted COVID-19 vaccine remains uncertain, but the company expects to have more clarity following an FDA advisory committee meeting in June.
The company plans to seek an EUA in Vietnam for ARCT-154, but some analysts have questioned its prospects in major markets like the US.